Analysis Pharmacovigilance

Rasonque authorised in the EU: what PV teams can and cannot yet say about daraxonrasib

The Commission has authorised Revolution Medicines' Rasonque, but the Union Register entry gives no indication or conditions, so PV planning must wait on documents not yet in view.

VigiEye editorial · Tue 17 Nov 2026

What happened

On 16 November 2026 the European Commission's Union Register recorded a marketing authorisation for Rasonque (daraxonrasib). The holder is Revolution Medicines Netherlands B.V.

The register entry is thin. It does not state the indication, and it does not say whether the authorisation carries conditions. Any commentary on Rasonque's therapeutic use, its safety profile or its post-authorisation obligations would therefore go beyond the record. This article does not offer any. What it can do is set out what a newly authorised product means for pharmacovigilance in general terms, and what to check once fuller documents are available.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources this analysis is based on

Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.

More analysis & opinionAll →